OKYO Pharma Execs to Discuss Urcosimod Strategy at Cantor Conference
Event summary
- OKYO Pharma execs to participate in fireside chat on September 10, 2026 at 8:35 AM ET
- Presenters include Chief Medical Officer Flavio Mantelli and Chief Development Officer Gary Jacob
- Company recently received positive FDA Type D meeting feedback on urcosimod
- Annual Report shows strengthened cash position ahead of Phase 3 trial
- Phase 3 trial for urcosimod in NCP treatment to enroll 111 patients
The big picture
OKYO Pharma's conference participation comes at a critical juncture as it prepares to advance urcosimod through Phase 3 trials. The positive FDA feedback validates its regulatory strategy, while the strengthened cash position suggests financial stability for clinical development. This aligns with broader industry trends of small-cap biopharma companies leveraging targeted investor conferences to build momentum for pivotal trials.
What we're watching
- Regulatory Validation
- Whether FDA's positive feedback will accelerate urcosimod's clinical timeline
- Execution Risk
- The pace at which OKYO can initiate and complete its Phase 3 trial
- Investor Sentiment
- How strengthened cash position impacts market perception of OKYO's runway